Neurobiology Of Relaxin-3/RXFP3 Systems: Anatomical And Functional Studies In Transgenic Mice
Funder
National Health and Medical Research Council
Funding Amount
$94,242.00
Summary
Mental illness is an economic and health burden worldwide, with huge costs in medical spending, lost productivity, poor quality of life for sufferers and mortality. Relaxin-3 is a peptide that acts widely within neural circuits to modulate brain activity that is altered in conditions such as anxiety and mood/sleep disorders. Our research assessing the effect of genetic removal of relaxin-3 signaling on behaviour will add to our knowledge of brain function and improve mental health outcomes.
Understanding The Pathophysiology Of Schizophrenia, Major Depressive Disorder And Bipolar Disorder As A Basis For Improving Treatments
Funder
National Health and Medical Research Council
Funding Amount
$804,106.00
Summary
The Applicant seeks to understand the causes of the schizophrenia, bipolar disorder and major depressive disorder, which affect over 20% of the Australian population. This research is important as drug design, based on chemical remodelling, has not significantly advanced initial breakthroughs in treating psychiatric disorders and there is now a widespread belief that new drugs will only come from understand their causes.
Differential Changes In Cortical Tumour Necrosis Factor Signalling In Mood Disorders And Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$642,078.00
Summary
Changes in inflammation-related pathways contribute to the symptoms of psychiatric disorders and tumour necrosis factor ? (TNF) is a protein central to regulating theses pathways. We have now shown that changes in pathways regulated by TNF are present in the brains of people with schizophrenia and mood disorders. This means that the symptoms experienced by those with the different disorders may be linked to differential changes in TNF-regulated pathways in the brain.